Efficacy and safety of mometasone furoate dry powder inhaler vs fluticasone propionate metered-dose inhaler in asthma subjects previously using fluticasone propionate

Annals of Allergy, Asthma and Immunology

Volumn 93, Issue 1, 2004, Pages 49-55

  Wardlaw, Andy ^a   Larivee, Pierre ^b   Eller, Jorg ^c   Cockcroft, Donald W ^d   Ghaly, Lisa ^e   Harris, Alan G ^e  

^a UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST   (United Kingdom)

^b CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKE   (Canada)

^c Markt I   (Germany)

^d ROYAL UNIVERSITY HOSPITAL   (Canada)

^e Integrated Therapeutics Group   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUTICASONE PROPIONATE; MOMETASONE FUROATE; ANDROSTANE DERIVATIVE; FLUTICASONE; PREGNANE DERIVATIVE;

ADOLESCENT; ADULT; ARTICLE; ASTHMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FORCED EXPIRATORY VOLUME; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; METERED DOSE INHALER; PATIENT SATISFACTION; POWDER INHALER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THRUSH; TREATMENT OUTCOME; AGED; MIDDLE AGED; NEBULIZER; PATHOPHYSIOLOGY; PEAK EXPIRATORY FLOW;

ADOLESCENT; ADULT; AGED; ANDROSTADIENES; ASTHMA; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; NEBULIZERS AND VAPORIZERS; PEAK EXPIRATORY FLOW RATE; PREGNADIENEDIOLS;

EID: 3843141741     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)61446-9     Document Type: Article

References (20)

1. Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention: NHLBI/WHO Workshop Report Update. Bethesda, MD: National Institutes of Health, National Heart, Lung and Blood Institute; 2002. Report No. 02-3659.
2. National Heart, Lung, and Blood Institute. National Asthma Education and Prevention Program (NAEPP), Expert Panel Report 2: Guidelines for the Diagnosis and Management of Asthma. Bethesda, MD: US Dept of Health and Human Services; 1997. Report No. 97-4051.
3. Pedersen S, O'Byrne P. A comparison of the efficacy and safety of inhaled corticosteroids in asthma. Allergy. 1997;52 (Suppl):1-34.
4. Bender B, Milgrom H, Rand C. Nonadherence in asthmatic patients: is there a solution to the problem? Ann Allergy Asthma Immunol. 1997;79:177-186.
5. Cochrane GM. Compliance in asthma. Eur Respir Rev. 1998;8:348-350.
6. Noonan M, Karpel JP, Bensch GW, et al. Comparison of once-daily to twice-daily treatment with mometasone furoate dry powder inhaler. Ann Allergy Asthma Immunol. 2001;86:36-43.
7. Nayak AS, Banov C, Corren J, et al. Once-daily mometasone furoate dry powder inhaler in the treatment of patients with persistent asthma. Ann Allergy Asthma Immunol. 2000;84:417-424.
8. Nathan RA, Nayak AS, Graft DF, et al. Mometasone furoate: efficacy and safety in moderate asthma compared with beclomethasone dipropionate. Ann Allergy Asthma Immunol. 2001;86:203-210.
9. Kemp JP, Berkowitz RB, Miller SD, Murray JJ, Nolop K, Harrison JE, Mometasone furoate administered once daily is as effective as twice-daily administration for treatment of mild-to-moderate persistent asthma. J Allergy Clin Immunol. 2000;106:485-492.
10. Bernstein DI, Berkowitz RB, Chervinsky P, et al. Dose-ranging study of a new steroid for asthma: mometasone furoate dry powder inhaler. Respir Med. 1999;93:603-612.
11. Fish JE, Karpel JP, Craig TJ, et al. Inhaled mometasone furoate reduces oral prednisone requirements while improving respiratory function and health-related quality of life in patients with severe persistent asthma. J Allergy Clin Immunol. 2000;106:852-860.
12. Glaxo Wellcome. Flovent Rotadisk Product Information. Research Triangle Park, NC: Glaxo Wellcome; 1999.
13. Crapo R. Reference values for lung function tests. Respir Care. 1989;34:626-637.
14. Quanjer P, Tammeling G, Cotes J, et al. Symbols, abbreviations and units: Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Eur Respir J Suppl. 1993;16:85-100.
15. Polgar G, Promadhat V. Pulmonary Function Testing in Children: Techniques and Standards. Philadelphia, PA: WB Saunders Co; 1971.
16. Kelly HW. Establishing a therapeutic index for the inhaled corticosteroids, part I: pharmacokinetic/pharmacodynamic comparison of the inhaled corticosteroids. J Allergy Clin Immunol. 1998;102:S36-S51.
17. Kamada AK, Szefler SJ, Martin RJ, et al. Issues in the use of inhaled glucocorticoids: the Asthma Clinical Research Network. Am J Respir Crit Care Med. 1996;153:1739-1748.
18. Turner-Warwick M. Epidemiology of nocturnal asthma. Am J Med. 1988;85:6-8.
19. Storms WW, Bodman SF, Nathan RA, Byer P. Nocturnal asthma symptoms may be more prevalent than we think. J Asthma. 1994;31:313-318.
20. Martin RJ, Banks-Schlegel S. Chronobiology of asthma. Am J Respir Crit Care Med. 1998;158:1002-1007.